1,1,5,5-Tetramethyl-3,3-diphenyltrisiloxane

We are 1,1,5,5-Tetramethyl-3,3-diphenyltrisiloxane CAS:17875-55-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1,1,5,5-Tetramethyl-3,3-diphenyltrisiloxane
CAS.NO:17875-55-7
Synonyms:Bis(dimethylsiloxy)diphenylsilane; Tetramethyl diphenyl dihydrogen trisiloxane;
3,3-diphenyl-1,1,5,5-tetramethyltrisiloxane; Trisiloxane,1,1,5,5-tetramethyl-3,3-diphenyl- ; 
Trisiloxane,1,1,5,5-tetramethyl-3,3-diphenyl-;
Molecular Formula:C16H24O2Si3
Molecular Weight:332.61700
 
Physical and Chemical Properties:
Density:0.994;
Boiling point:292oC;
Flash point:130oC;
Index of Refraction:1.500;
 
Specification:
Appearance:Colorless clear liquid
Purity:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used as crosslinkers for liquid silicone rubber, phenyl silicone rubber and phenyl resin.

1,1,5,5-Tetramethyl-3,3-diphenyltrisiloxane


Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.4-amino-6- (2-metil-2-propanil) -3-tioxo-3,4-dihidro-1,2,4-triazi n-5 (2H) -ona CAS:57989-76-1 Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.10-(2-Naphthyl)Anthracene-9-Boronic Acid In these situations, the API is not a single substance but the culmination of various ingredients.4-Fluoro-2-methylaniline CAS:452-71-1 In these situations, the API is not a single substance but the culmination of various ingredients.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
Glabridin View Details
2-Bromovaleric acid View Details
3-Amino-4-(trifluoromethoxy)BromoBenzene View Details
1-(bromomethyl)-4-fluoro-2-(trifluoromethyl)benzene manufacturer 2-Chloro-1,3-bis(dimentylamino)trimethinium hexafluorophosphate manufacturer (2-Chloroethyl)benzene manufacturer 2-Fluoro-3-trifluoromethylpyridine manufacturer (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate manufacturer